As we previously reported, Amgen appealed the Southern District of Florida’s judgment of non-infringement in favor of Apotex in litigation regarding Apotex’s proposed filgrastim and pegfilgrastim biosimilars. Today the Federal Circuit issued a decision affirming the district court’s finding of non-infringement.
We will post a summary of the opinion later today.